BRIEF published on 09/23/2026 at 21:41, 1 day 8 hours ago ABIONYX: 2026 Half-Year Results and Future Strategies Research And Development Treasury France 2030 ABIONYX Pharma 2026 Financial Results
BRIEF published on 09/23/2026 at 21:41, 1 day 8 hours ago ABIONYX : Résultats Semestriels 2026 et Stratégies Future Recherche Et Développement Trésorerie France 2030 ABIONYX Pharma Résultats Financiers 2026
BRIEF published on 09/23/2026 at 21:41, 1 day 8 hours ago ABIONYX Pharma publie ses résultats semestriels pour 2026 Résultats Financiers Produits Biopharmaceutiques Rapport Sur Les Revenus Recherche Sur La Septicémie Déficit En LCAT
BRIEF published on 09/23/2026 at 21:41, 1 day 8 hours ago ABIONYX Pharma Reports Half-Year Results for 2026 Financial Results Biopharmaceuticals Revenue Report LCAT Deficiency Sepsis Research
PRESS RELEASE published on 09/23/2026 at 21:36, 1 day 8 hours ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce ses résultats financiers du 1er semestre 2026 avec une trésorerie de 26,9 M€ avant encaissement des Crédits d’Impôt Recherche et des aides du plan France 2030, perspectives axées sur l'exécution des programmes Résultats Financiers Trésorerie Plan France 2030 ABIONYX Pharma Sepsis
PRESS RELEASE published on 09/23/2026 at 21:36, 1 day 8 hours ago Inside Information / Other news releases ABIONYX Pharma announces half-year financial results for 2026 with emphasis on cash balance, revenue, and expenses. Focus on innovative therapies for sepsis and LCAT deficiency under France 2030 plan Half-year Results France 2030 Plan ABIONYX Pharma Sepsis LCAT Deficiency
BRIEF published on 08/27/2026 at 19:04, 28 days 10 hours ago ABIONYX Pharma Updates on Mid-Year 2026 Financials Cash Position Financial Update Ophthalmology ABIONYX Pharma 2026 Revenue
BRIEF published on 08/27/2026 at 19:04, 28 days 10 hours ago ABIONYX Pharma fait le point sur ses résultats financiers de mi-année 2026 Mise À Jour Financière Ophtalmologie ABIONYX Pharma Position De Trésorerie Recettes De 2026
PRESS RELEASE published on 08/27/2026 at 18:59, 28 days 10 hours ago Informations privilégiées / Autres communiqués ABIONYX Pharma révèle un chiffre d’affaires consolidé de 1,9 M€ et une trésorerie de 26,9 M€ au 30 juin 2026. La société biopharmaceutique annonce des résultats financiers et une avancée dans le développement de thérapies innovantes Chiffre D'affaires Développement Trésorerie ABIONYX Pharma Thérapies Innovantes
PRESS RELEASE published on 08/27/2026 at 18:59, 28 days 10 hours ago Inside Information / Other news releases ABIONYX Pharma updates activity and cash position for H1 2026: revenue of €1.9M, cash balance of €26.9M before Research Tax Credits and grants. Company focuses on innovative therapies for sepsis Revenue Cash Position Innovative Therapies ABIONYX Pharma Activity Update
Published on 09/25/2026 at 00:30, 5 hours 12 minutes ago Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 5 hours 27 minutes ago CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 7 hours 41 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 14 hours 47 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/25/2026 at 02:45, 2 hours 57 minutes ago Huagui Group: un acteur mondial sur deux marchés aquatiques de plus de 100 milliards de RMB, tandis que la racine de lotus de Honghu se classe au premier rang pour sa teneur en antioxydants
Published on 09/25/2026 at 02:45, 2 hours 57 minutes ago Huagui Group: A Global Player Across Two RMB100-Billion Aquatic Markets, as Honghu Lotus Root Ranks No. 1 in Antioxidant Content
Published on 09/24/2026 at 20:29, 9 hours 13 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 10 hours 42 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 11 hours 2 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:31, 11 hours 11 minutes ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 11 hours 42 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 11 hours 42 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
